RESEARCH ARTICLE
Comparison of Visual Outcomes and Patient Satisfaction Following Cataract Surgery with Two Monofocal Intraocular Lenses: Clareon® vs AcrySof® IQ Monofocal
Smita Agarwal1, Erin Thornell2, *
Article Information
Identifiers and Pagination:
Year: 2021Volume: 15
First Page: 144
Last Page: 150
Publisher ID: TOOPHTJ-15-144
DOI: 10.2174/1874364102115010144
Article History:
Received Date: 22/2/2021Revision Received Date: 18/5/2021
Acceptance Date: 30/5/2021
Electronic publication date: 16/09/2021
Collection year: 2021
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Aim:
This study aimed to compare the performance of two monofocal Intraocular Lenses (IOL) platforms.
Background:
The Clareon® Intraocular Lens (IOL) is a relatively new monofocal lens platform designed to improve postoperative results compared to other monofocal platforms.
Objective:
This study aimed to assess and compare the visual and refractive outcomes, and incidence of YAG capsulotomy of the Clareon® IOL and a standard non-preloaded AcrySof® monofocal IOL following contralateral implantation in patients undergoing cataract surgery.
Methods:
A total of 20 patients (40 eyes; 12 female, average age 72.8±6.4 years) who had undergone contralateral implantation of an AcrySof® IQ monofocal lens (SN60WF or SN6AT; Alcon; Texas, USA) and a Clareon®monofocal lens (CNAOT0; Alcon; Texas, USA) were selected. Uncorrected Distance Visual Acuity (UDVA), Contrast Sensitivity (CS), kinetic perimetry, and refraction were measured 1 month following the second surgery and subjective vision was measured 6 months following the second surgery using a quality-of-life questionnaire.
Results:
There was no difference in postoperative UDVA (P=0.94), CS (P>0.05), or refraction (P=0.64) between eyes that received the Clareon® and AcrySof® IQ lenses. Clareon® eyes had a higher incidence of glare/haloes and positive dysphotopsia while AcrySof® IQ eyes had a higher incidence of negative dysphotopsia. Patient satisfaction was similar between the groups (P=0.86), although 25% of patients reported more clarity in the eye that received the Clareon® lens. The incidence of posterior capsular opacification was low for both groups.
Conclusion:
Clareon® and AcrySof® IQ lenses perform similarly, providing good refractive, visual, and subjective outcomes. Clareon® is available as a preloaded lens option and may reduce PCO and the need for Nd: YAG capsulotomy.
